Skip to main content
TipRanks
Go Ultimate75% OFF

Mochida Pharmaceutical Co., Ltd. (4534) AI Stock Analysis

1 Followers
JP:4534

Mochida Pharmaceutical Co., Ltd.

(TSE/TYO:4534)

Select Model
Rating:71Outperform
Price Target:JPY 3,729.00▲(12.15% Upside)
Action:reiterated
Date:11/18/26

The overall score of 71 reflects a company with strong fundamentals and an attractive valuation, tempered by cash flow instability. The primary strengths are a rock-solid, low-debt balance sheet and a very low P/E ratio of 11.1, which together suggest a margin of safety. Positive technical momentum supports the near-term outlook. The main risk is the poor cash flow performance in FY2026, which introduces uncertainty about the company's ability to consistently convert profits into cash.

Positive Factors
Conservative Balance SheetMochida’s conservative balance sheet provides financial flexibility to sustain research, product development, and commercial operations. Low historical leverage also reduces financing pressure and improves resilience if earnings weaken or the pharmaceutical environment becomes less favorable.
Negative Factors
Unstable Cash ConversionVolatile cash generation makes reported earnings less dependable as a source of internally funded investment. Repeated negative operating and free cash flow can constrain flexibility, increase reliance on balance-sheet resources, and complicate planning for development and commercial priorities.

Mochida Pharmaceutical Co., Ltd. (4534) vs. iShares MSCI Japan ETF (EWJ)

-10%0%10%20%30%40%JP:4534+1.36%EWJ+15.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 113.15B
Dividend Yield
2.48%
Average Volume (3M)
44.59K
Price to Earnings (P/E)
10.9
Beta (1Y)
0.64
Revenue Growth
15.85%
EPS Growth
60.55%
Country
Japan
Employees
1,479
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Mochida Pharmaceutical Co., Ltd. Business Overview & Revenue Model

Company Description

Established in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmaceuti...

How the Company Makes Money

Mochida Pharmaceutical primarily makes money by selling pharmaceutical products, with revenue driven mainly by domestic sales of prescription drugs. Its core revenue model is product-based: it develops and/or manufactures medicines and generates inco...

Mochida Pharmaceutical Co., Ltd. Financial Statement Overview

Summary

Solid income statement with 9.9% revenue growth and a 39% net income increase, paired with a very strong, low-leverage balance sheet. However, significant cash flow volatility and a negative FY2026 operating cash flow of ¥-7.35B raise concerns about cash generation sustainability, tempering the overall financial health score.

Income Statement

74Positive

Balance Sheet

86Very Positive

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue126.33B116.95B105.16B102.89B103.26B110.18B
Gross Profit59.50B56.26B53.79B52.07B55.12B59.55B
EBITDA15.72B13.13B11.07B8.61B11.18B17.08B
Net Income10.75B7.90B5.68B4.55B6.65B10.57B
Balance Sheet
Total Assets184.91B182.72B163.56B162.30B161.04B165.93B
Cash, Cash Equivalents and Short-Term Investments28.57B31.06B51.15B46.79B60.51B61.91B
Total Debt10.00B10.00B342.00M369.00M178.00M0
Total Liabilities42.56B42.39B32.87B34.33B34.26B37.28B
Stockholders Equity142.35B140.33B130.69B127.97B126.78B128.65B
Cash Flow
Free Cash Flow0-10.04B7.19B-9.78B5.13B4.47B
Operating Cash Flow0-7.35B9.35B-7.48B7.30B7.46B
Investing Cash Flow0-16.85B17.36B74.00M-2.95B-2.01B
Financing Cash Flow07.03B-2.87B-6.39B-6.88B-5.96B

Mochida Pharmaceutical Co., Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price3325.00

Price Trends

50DMA3223.91Positive
100DMA3186.90Positive
200DMA3324.67Positive

Market Momentum

MACD36.68Negative
RSI54.79Neutral
STOCH70.00Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4534, the sentiment is Positive. The current price of 3325.00 is above the 20-day moving average (MA) of 3287.25, above the 50-day MA of 3223.91, and above the 200-day MA of 3324.67, indicating a bullish trend. The MACD of 36.68 indicates Negative momentum. The RSI at 54.79 is Neutral, neither overbought nor oversold. The STOCH value of 70.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4534.

Mochida Pharmaceutical Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4534 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4547JP:454773OutperformJPY 181.97B16.554.95%4.60%5.87%-21.16%
JP:4534JP:453471OutperformJPY 113.15B10.937.68%2.48%15.85%60.55%
JP:4569JP:456958NeutralJPY 58.75B160.06―4.24%-6.48%-95.83%
JP:4887JP:488756NeutralJPY 166.15B18.57―3.36%2.43%―
JP:4521JP:452153NeutralJPY 137.41B15.726.11%4.98%5.43%1167.62%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4553JP:455350NeutralJPY 166.84B42.262.10%2.36%7.06%-81.10%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%JP:4534JP:4521JP:4547JP:4553JP:4569JP:4887Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4534 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4534Mochida Pharmaceutical Co., Ltd.3325.00103.333.21%
JP:4521Kaken Pharmaceutical Co 3815.00290.168.23%
JP:4547Kissei Pharmaceutical Co 4455.00316.017.63%
JP:4553Towa Pharmaceutical Co 3390.00450.7615.34%
JP:4569KYORIN Pharmaceutical Co.,Ltd.1108.00-278.19-20.07%
JP:4887SAWAI GROUP HOLDINGS Co., Ltd.1667.00-178.64-9.68%

Mochida Pharmaceutical Co., Ltd. Corporate Events

Mochida Pharmaceutical Reports Strong First-Half Earnings Growth

Nov 9, 2026

Mochida Pharmaceutical, a Japan-listed pharmaceutical company, reported strong first-half performance for the six months ended September 30, 2026. Net sales increased 17.1% year on year to ¥64.4 billion, while operating profit rose 43.0% to ¥7.1 bill...

Mochida Pharmaceutical Repurchases ¥275.4 Million of Shares

Nov 2, 2026

Mochida Pharmaceutical repurchased 86,100 common shares for ¥275.4 million during October, using market purchases on the Tokyo Stock Exchange. The transaction forms part of the company’s ongoing share-buyback program and represents continued capital...

Mochida Pharmaceutical Advances TSE Share Buyback Under Board-Approved Program

Oct 1, 2026

Mochida Pharmaceutical has disclosed the latest status of its ongoing share buyback program authorized under Japan’s Companies Act. Between September 1 and September 30, 2026, the company repurchased 57,400 of its own common shares via market purchas...

Mochida Pharmaceutical Steps Up Share Buybacks Under 2026 Repurchase Program

Sep 1, 2026

Mochida Pharmaceutical Co., Ltd. has continued its share repurchase program, buying 82,000 of its own common shares on the Tokyo Stock Exchange between August 1 and August 31, 2026, at a total cost of ¥264.7 million under a discretionary dealing cont...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026